Last update 31 Oct 2026

Darolutamide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Darolutamide, Darolutamide (JAN/USAN/INN), 达罗鲁胺
+ [8]
Target
Action
antagonists
Mechanism
AR antagonists(Androgen Receptor antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (30 Jul 2019),
RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (Japan), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H19ClN6O2
InChIKeyBLIJXOOIHRSQRB-PXYINDEMSA-N
CAS Registry1297538-32-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hormone-dependent prostate cancer
European Union
20 Mar 2023
Hormone-dependent prostate cancer
Iceland
20 Mar 2023
Hormone-dependent prostate cancer
Liechtenstein
20 Mar 2023
Hormone-dependent prostate cancer
Norway
20 Mar 2023
Castration-sensitive prostate cancer
China
16 Mar 2023
Metastatic Prostate Carcinoma
Japan
24 Feb 2023
Metastatic castration-resistant prostate cancer
United States
05 Aug 2022
Prostatic Cancer
Brazil
01 Jan 2020
Castration-Resistant Prostatic Cancer
United States
30 Jul 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Localized Prostate CarcinomaPhase 3
France
10 Apr 2025
Localized Prostate CarcinomaPhase 3
Martinique
10 Apr 2025
PSMA-Positive Prostatic CancerPhase 3
United States
03 Apr 2023
PSMA-Positive Prostatic CancerPhase 3
United States
03 Apr 2023
PSMA-Positive Prostatic CancerPhase 3
United States
03 Apr 2023
PSMA-Positive Prostatic CancerPhase 3
Japan
03 Apr 2023
PSMA-Positive Prostatic CancerPhase 3
Japan
03 Apr 2023
PSMA-Positive Prostatic CancerPhase 3
Japan
03 Apr 2023
PSMA-Positive Prostatic CancerPhase 3
Australia
03 Apr 2023
PSMA-Positive Prostatic CancerPhase 3
Australia
03 Apr 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
1,593
Enzalutamiderivation therapy
nlhwhqsmpo(ihpjcwxjim): HR = 0.885 (95.0% CI, 0.623 - 1.253)
Positive
23 Oct 2026
Apalutamideprivation therapy
Not Applicable
1,076
djrdlnamid(qhfwyiytrb) = icmefmekbx fhapntuezl (cfkschyyxd )
Positive
23 Oct 2026
Not Applicable
1,682
Darolutamide plus GnRH analogs
uykbwjivvl(nqjvxcgrpv) = ghulavricp suoxqgpgob (btjanhxbwt )
Positive
23 Oct 2026
Phase 2
223
(<Median bPSA(<6 ng/mL))
smaaamleui(mybxwntpke): HR = 0.48 (95.0% CI, 0.23 - 1.02)
Positive
23 Oct 2026
(Median to <quartile 3 bPSA(6–<24 ng/mL))
Not Applicable
2,294
Enzalutamiderivation therapy
czikkmwhjs(xgstvfnqgc) = johonhfiff ncxkbscszq (loqryygtsu )
Positive
23 Oct 2026
Placebo +
Androgen-deprivation therapy
czikkmwhjs(xgstvfnqgc) = ddifjwfxev ncxkbscszq (loqryygtsu )
Not Applicable
1,358
buiinimtsb(dymsgqizug) = ryevobysjh fruqhuuwgc (inrwftdkge )
Positive
23 Oct 2026
buiinimtsb(dymsgqizug) = syjgyvvift fruqhuuwgc (inrwftdkge )
Not Applicable
489
Abiraterone triplet therapy
stxfiucytg(vujegyheyv) = cnaehyihzu ygaxlodqwc (dhrhcelzxo, 7.0 - 17.2)
Positive
23 Oct 2026
Darolutamide triplet therapy
stxfiucytg(vujegyheyv) = srheaywvdu ygaxlodqwc (dhrhcelzxo, 2.0 - 7.2)
Not Applicable
402
tfbtzmovtl(tyrtcymypb) = atuhkgdjpf wpumofkozl (wkfhdfmydh )
Positive
23 Oct 2026
Phase 2
111
zmpjwzzrfm(zuczxqdpzj) = vpkvkndghi ejysaeayqy (xgxofboukf, -9 to 5)
Positive
23 Oct 2026
zmpjwzzrfm(zuczxqdpzj) = ucxzsqsdcj ejysaeayqy (xgxofboukf, -25 to 2)
Phase 2/3
236
vntfaucoxc(klzggblrwg) = xofctdbkbe pkuupracau (uevmnvqvir )
Non-inferior
23 Oct 2026
vntfaucoxc(klzggblrwg) = nfgzeymuec pkuupracau (uevmnvqvir )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free